The Wisconsin Opioid Overdose Response Center recently received an extension to the grant they obtained in September of 2024 to keep their work towards getting opioid harm reduction supplies and ...
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results